Pleuromulin Ursodeoxycholic Acid Ester Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid development of drug-resistant bacteria poses a significant challenge in treating infections, as current antibacterial drugs are ineffective against multidrug-resistant bacteria such as Escherichia coli, Staphylococcus aureus, Acinetobacter baumannii, and Mycobacterium tuberculosis.
Innovation Solution
A pleuromulin ursodeoxycholic acid ester is synthesized by reacting pleuromulin with ursodeoxycholic acid using a method involving a coupling agent like DCC and a catalytic amount of 4-DMAP, under controlled temperature and solvent conditions, to produce a compound with enhanced antibacterial activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibacterial drugs are used, then treatment of common bacterial infections is effective, but they are ineffective against multidrug-resistant bacteria
Solution Approach 1:
The patent creates a composite molecular structure by coupling pleuromulin (a veterinary antibiotic) with ursodeoxycholic acid (a bile acid) to form a new ester compound. This composite structure combines the antibacterial properties of pleuromulin with the biocompatibility and solubility enhancements from ursodeoxycholic acid, resulting in a compound that maintains activity against resistant bacteria while improving pharmacological properties.
Solution Approach 2:
The patent modifies the chemical structure of pleuromulin by changing parameters such as molecular weight, solubility, and stereochemical configuration through esterification with ursodeoxycholic acid. These parameter changes enable the compound to overcome bacterial resistance mechanisms while retaining core antibacterial activity.
2Reliability
If pleuromulin is modified by ursodeoxycholic acid structure, then antibacterial activity against drug-resistant bacteria is enhanced, but synthesis complexity increases
Solution Approach 1:
The patent employs dicyclohexylcarbodiimide (DCC) as a coupling intermediary to facilitate the esterification reaction between pleuromulin and ursodeoxycholic acid. This intermediary enables the formation of the ester bond under mild conditions without requiring complex multi-step synthesis procedures, thus simplifying the overall process while achieving the desired molecular modification.
Solution Approach 2:
The patent replaces complex mechanical separation and purification methods with a streamlined process using silica gel column chromatography for final purification. The reaction conditions are optimized to minimize byproduct formation, reducing the need for complex separation steps and simplifying the overall synthesis protocol.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pleuromulin ursodeoxycholic acid ester demonstrates excellent antibacterial activity, including effectiveness against drug-resistant bacteria, as shown by significant inhibition zones in in vitro tests, making it a promising candidate for treating multidrug-resistant infections.
Implementation Method 1
reacting a compound of formula (II) with a compound of formula (III) to obtain the compound of formula (I)... adding an organic solvent and coupling agent DCC (N,N'-dicyclohexylcarbodiimide)
Implementation Method 2
adding a catalytic amount of 4-DMAP (4-dimethylaminopyridine) and the compound of formula (II) to the reaction mixture
Implementation Method 3
heating the reaction mixture at 20-60° C. for 8-12 hours
Implementation Method 4
extracting the reaction mixture with ethyl acetate to obtain a crude product
Implementation Method 5
purifying the crude product on a silica gel fresh chromatography column with dichloromethane and methanol as an eluent
Data Source
AI summary
A compound with antibacterial activity having the following formula (I):is disclosed. A method of preparing the compound of formula (I) is also disclosed.